fashion -WSS

fashion

author：explore 2025-08-28 06:24:38 - browse：925

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Maui wildfire now ranks as the fifth

focus

WSS

Maui wildfire now ranks as the fifth

Bispecific antibodies are next new thing in cancer immunotherapy

Dozens dead from Maui wildfires: What we know about the victims

Biden administration begins canceling student loan debt for 804,000 borrowers

Patients, doctors are clashing about side effects of hormonal birth control

Patients, doctors are clashing about side effects of hormonal birth control

leisure time

fashion

hotspot

Activists slam private health insurers over coverage restrictions

A public health expert passes on football's full body collisions for youths

Alkermes shareholders re

Living organ donors deserve priority status for transplants

Alkermes shareholders re

Hospitals are dialing back on venture capital investing

In age of alternative facts, a scholarly course on calling out crap

Senators push IRS to launch nonprofit hospital probe

Hepatitis C has a cure — but many Americans still lack access to it

Patients, digital health players weigh in on FTC's data privacy plan

entertainment

Montana youths win climate lawsuit against state for promoting fossil fuels

A public health expert passes on football's full body collisions for youths

Inside the rise of 'mukbang' eating videos

Inside the rise of 'mukbang' eating videos

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Novo: Oral version of Ozempic leads to 15% weight loss

hotspot

entertainment

focus

focus